Calif. Prop 61 Raises Industry Concerns Over Ripple Effect
Executive Summary
Industry executives are speaking out against the measure that would require California state agencies to pay no more than the US Department of Veterans Affairs pay for drugs.
You may also be interested in...
Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC
As industry begins to organize around broader self-regulation on drug pricing, PwC Partner Rick Judy expects pharma companies to announce more social contracts with consumers. Industry self-regulation on prices is one of 10 top health issues for 2017 identified by the consulting firm.
California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead
A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.
California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead
A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.